1. Scrip
  2. >>Archive

TetraPhase's Series C

 
• By Carlene Olsen

Anti-infective developer TetraPhase Pharmaceuticals announced June 1 its $45 million Series C financing, with participation from a syndicate of new and existing backers. The financing is one of the richest of the year, just below the April $56 million Series C pulled in by Achaogen, which is also developing antibiotics for drug resistant diseases. And it far exceeds the average Series C financing of $19.77 million raised between January and May of this year.

Anti-infective developer Tetraphase Pharmaceuticals Inc. announced June 1 its $45 million Series C financing, with participation from a syndicate of new and existing backers. [See Deal] The money will be used to advance its lead candidate, an intravenous antibiotic against gram-negative pathogens, into Phase II studies later this year. Funds will also be used to move the biotech's two novel IV/oral antibiotics into the clinic: TP-2758, for complicated urinary tract infections (cUTI); and TP-834, for the treatment of community acquired bacterial pneumonia (CABP).

The financing is one of the richest of the year, just below the April $56 million Series C pulled in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Citeline Japan Awards 2025 - Enter Now!

 
• By Ian Haydock and Lisa Takagi

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.